Pfizer, Ranbaxy Can't Pause Lipitor Pay-For-Delay Suit

Law360, New York (October 25, 2012, 7:43 PM EDT) -- A New Jersey judge has refused to halt multidistrict antitrust litigation challenging patent infringement settlements Pfizer Inc. reached over its cholesterol treatment Lipitor, ruling that waiting for the U.S. Supreme Court to take and decide similar suits over pay-for-delay deals would stall the case too long.

U.S. District Judge Peter G. Sheridan on Oct. 19 rejected a request from defendants Pfizer, Ranbaxy Inc. and others to stay the MDL until the Supreme Court decides whether it will review a Third Circuit case the plaintiffs have indicated...
To view the full article, register now.